Two experts give away their favourite pharmacy stock

The iShares U.S. Pharmaceuticals ETF is continuing up since March 8th, but it’s not too late to hop onto the rally. There still are pharmacy stocks that are attractive buys at current valuations.

Walgreens Boots Alliance Inc (NASDAQ: WBA)

One such name is Walgreens that reported marketing-beating results for its fiscal Q2 last week. Making a case for this stock on CNBC’s “Halftime Report”, Hightower’s Stephanie Link said:

The stock is down 11% year-to-date. 8.5 times earnings, I like what this new management is doing in terms of investing. I would buy it on weakness.

Walgreens is looking at low-single-digit growth in adjusted EPS this year. According to CEO Roz Brewer, supply constraints are easing but inflation remains a challenge.

CVS Health Corporation (NYSE: CVS)

Another laggard in the pharmacy space that’s still attractive in terms of valuation is CVS Health Corp. Down 10% from its high in early February, the stock is a recommendation from Cerity Partners’ Jim Lebenthal.

I think it’s an all-weather stock. If you get a punk market, you’ll still need healthcare, they’ll still have cash flows to pay down the debt on their balance sheet. If things go well, the same will happen. This is the stock to own.

In its latest reported quarter, CVS also topped Wall Street expectations and offered upbeat guidance for the full year.  

The post Two experts give away their favourite pharmacy stock appeared first on Invezz.

Disclaimer:, its managers, its employees, and assigns (collectively "The Company") do not make any guarantee or warranty about what is advertised above. Information provided by this website is for research purposes only and should not be considered as personalized financial advice. The Company is not affiliated with, nor does it receive compensation from, any specific security. The Company is not registered or licensed by any governing body in any jurisdiction to give investing advice or provide investment recommendation. Any investments recommended here should be taken into consideration only after consulting with your investment advisor and after reviewing the prospectus or financial statements of the company.

Copyright © 2022 All Rights Reserved.

To Top